Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
SALBUTAMOL (SALBUTAMOL SULFATE)
GLAXOSMITHKLINE INC
R03CC02
SALBUTAMOL
1MG
SOLUTION
SALBUTAMOL (SALBUTAMOL SULFATE) 1MG
INTRAVENOUS
5 ML DOSE X 5
Prescription
SELECTIVE BETA 2-ADRENERGIC AGONISTS
Active ingredient group (AIG) number: 0108887007; AHFS:
APPROVED
2001-07-26
_2014-07-03/131-pristine-eng-ventolin-IV-infusion-sol.doc _ _ _ _Page 1 of 22_ _ _ _ _ _ _ PRODUCT MONOGRAPH PR VENTOLIN ® I.V. INFUSION SOLUTION salbutamol sulphate for injection 1000 mcg/mL BP Bronchodilator (beta 2 -adrenergic agonist) GlaxoSmithKline Inc. 7333 Mississauga Road Mississauga, Ontario L5N 6L4 Date of Revision: July 3, 2014 Submission Control No: 173386 _©_ _ 2014 GlaxoSmithKline Inc. All Rights Reserved _ _®_ _VENTOLIN is a registered trademark, used under license by GlaxoSmithKline Inc. _ _2014-07-03/131-pristine-eng-ventolin-IV-infusion-sol.doc _ _ _ _Page 2 of 22_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................7 DRUG INTERACTIONS ....................................................................................................8 DOSAGE AND ADMINISTRATION ................................................................................9 OVERDOSAGE ................................................................................................................11 ACTION AND CLINICAL PHARMACOLOGY ............................................................12 STORAGE AND STABILITY ..........................................................................................12 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................12 PART II: SCIENTIFIC INFORMATION ...............................................................................13 PHARMACEUTI Կարդացեք ամբողջական փաստաթուղթը